Greenville, SC – According to filings with the U.S. Securities and Exchange Commission, Zylo Therapeutics is raising $3,182,500.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Scott Pancoast played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Zylo Therapeutics
Zylo is bridging the innovation gap in topical drug delivery using patented silica particles called Z-pods. The technology–licensed from Einstein College of Medicine forms the basis of our disruptive topical delivery system that overcomes bioavailability challenges by providing: (i) improved stability; (ii) sustained release; (iii) targeting of the hair follicle unit (iv) reduced enzymatic degradation; and (v) the ability to provide sustained release of nitric oxide.

To learn more about Zylo Therapeutics, visit http://www.zylotherapeutics.com/

Contact:
Scott Pancoast, Chief Executive Officer
858-775-6710
spancoast@zylotherapeutics.com
https://www.linkedin.com/in/scott-pancoast-743a257/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved